Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience

REFERENCES

1. 1.↵
   1. Znaor A,
   2. Lortet-Tieulent J,
   3. Laversanne M,
   4. Jemal A,
   5. Bray F

   International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015 3; 67 3: 519- 530. doi: 10.1016/j.eururo.2014.10.002. pmid:25449206

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Sun M,
   2. Thuret R,
   3. Abdollah F,
   4. et al.

   Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011 1; 59 1: 135- 141. doi: 10.1016/j.eururo.2010.10.029. pmid:21035250

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Leibovich BC,
   2. Blute ML,
   3. Cheville JC,
   4. et al.

   Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003 4 1; 97 7: 1663- 1671. pmid:12655523

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Park YH,
   2. Baik KD,
   3. Lee YJ,
   4. Ku JH,
   5. Kim HH,
   6. Kwak C

   Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis. BJU Int. 2012 12; 110 11 Pt B: E553- E558. doi: 10.1111/j.1464-410X.2012.11246.x. pmid:22578274

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Kroeger N,
   2. Choueiri TK,
   3. Lee JL,
   4. et al.

   Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol. 2014 6; 65 6: 1086- 1092. doi: 10.1016/j.eururo.2013.07.031. pmid:23916693

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Adamy A,
   2. Chong KT,
   3. Chade D,
   4. et al.

   Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol. 2011 2; 185 2: 433- 438. doi: 10.1016/j.juro.2010.09.100. pmid:21167521

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Brookman-May S,
   2. May M,
   3. Shariat SF,
   4. et al.

   Members of the CORONA project and the SATURN project. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol. 2013 9; 64 3: 472- 477. doi: 10.1016/j.eururo.2012.06.030. pmid:22748912

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Heng DY,
   2. Xie W,
   3. Regan MM,
   4. et al.

   External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013 2; 14 2: 141- 148. doi: 10.1016/S1470-2045(12)70559-4. pmid:23312463

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Heng DY,
   2. Xie W,
   3. Regan MM,
   4. et al.

   Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 12 1; 27 34: 5794- 5799. doi:10.1200/JCO.2008.21.4809. pmid:19826129

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Eisenhauer EA,
    2. Therasse P,
    3. Bogaerts J,
    4. et al.

    New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 1; 45 2: 228- 247. doi:10.1016/j.ejca.2008.10.026. pmid:19097774

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed August 4, 2017.
12. 12.↵
    1. Santoni M,
    2. Conti A,
    3. Porta C,
    4. et al.

    Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. J Urol. 2015 1; 193 1: 41- 47. doi: 10.1016/j.juro.2014.07.011. pmid:25046616

    OpenUrlCrossRefPubMed
13. 13.↵
    1. McKay RR,
    2. Kroeger N,
    3. Xie W,
    4. et al.

    Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014 3; 65 3: 577- 584. doi: 10.1016/j.eururo.2013.08.012. pmid:23962746

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Grassi P,
    2. Verzoni E,
    3. Mariani L,
    4. et al.

    Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer. 2013 12; 11 4: 484- 488. doi: 10.1016/j.clgc.2013.04.022. pmid:23791435

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Kalra S,
    2. Atkinson BJ,
    3. Matrana MR,
    4. et al.

    Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016 5; 117 5: 761- 765. doi: 10.1111/bju.13185. pmid:26032863

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Valenca LB,
    2. Hirsch MS,
    3. Choueiri TK,
    4. Harshman LC

    Non-clear cell renal cell carcinoma, part 2: therapy. Clin Adv Hematol Oncol. 2015 6; 13 6: 383- 391. pmid:26352894

    OpenUrlPubMed
17. 17.↵
    1. Kroeger N,
    2. Xie W,
    3. Lee JL,
    4. et al.

    Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013 8 15; 119 16: 2999- 3006. doi:10.1002/cncr.28151. pmid:23696129

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Motzer RJ,
    2. Hutson TE,
    3. Cella D,
    4. et al.

    Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 8 22; 369 8: 722- 731. doi: 10.1056/NEJMoa1303989. pmid:23964934

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Santoni M,
    2. Buti S,
    3. Conti A,
    4. et al.

    Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 2015 12; 10 4: 517- 522. doi: 10.1007/s11523-014-0356-3. pmid:25559290

    OpenUrlCrossRefPubMed